SEK 3.21
(2.56%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 | 90.87 Million SEK | 24.62% |
2023 | 72.91 Million SEK | -16.09% |
2022 | 86.9 Million SEK | 103.01% |
2021 | 42.8 Million SEK | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q4 | 90.87 Million SEK | 0.12% |
2024 Q3 | 90.76 Million SEK | 7.89% |
2024 Q2 | 84.12 Million SEK | -10.59% |
2024 Q1 | 94.09 Million SEK | 29.04% |
2023 FY | 72.91 Million SEK | -16.09% |
2023 Q1 | - SEK | 0.0% |
2023 Q4 | 72.91 Million SEK | -3.14% |
2023 Q3 | 75.27 Million SEK | -2.34% |
2023 Q2 | 77.08 Million SEK | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
AcuCort AB | 58.5 Million SEK | -55.316% |
AlzeCure Pharma AB (publ) | 32 Million SEK | -183.963% |
BioGaia AB (publ) | 2.33 Billion SEK | 96.105% |
Enzymatica AB (publ) | 125.91 Million SEK | 27.829% |
Enorama Pharma AB (publ) | 34.38 Million SEK | -164.275% |
Gabather AB (publ) | 2.93 Million SEK | -2994.007% |
Klaria Pharma Holding AB (publ.) | 73.12 Million SEK | -24.277% |
Moberg Pharma AB (publ) | 634.73 Million SEK | 85.684% |
Nanexa AB (publ) | 132.25 Million SEK | 31.292% |
ODI Pharma AB | 12.27 Million SEK | -640.294% |
Orexo AB (publ) | 786.6 Million SEK | 88.448% |
Probi AB (publ) | 1.55 Billion SEK | 94.139% |
Swedencare AB (publ) | 9.52 Billion SEK | 99.046% |
Swedish Orphan Biovitrum AB (publ) | 74.02 Billion SEK | 99.877% |
Toleranzia AB | 160.42 Million SEK | 43.357% |
Vivesto AB | 355.87 Million SEK | 74.466% |